课题基金 / 基金详情

PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER

PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER
紫杉醇与紫杉醇 PSC833 治疗乳腺癌的 II 期随机研究
批准号：
6303709
负责人：
DARCY V SPICER
金额：
$3.56万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303709
关键词：
breast neoplasms clinical research combination cancer therapy cyclosporines female human subject human therapy evaluation neoplasm /cancer chemotherapy paclitaxel pharmacokinetics women's health

项目摘要

项目成果

DARCY V SPICER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To evaluate the response rate, time to treatment failure, and pharmacokinetics of paclitaxel (Taxol) with and without PSC 833 (a cyclosporin analogue which is active in reversing multidrug resistance gene expression in cancer cells) in advanced hormonally-insensitive breast cancer subjects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SCCISARS 2: An e-Solution to Protect Human Subjects
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER
海外基金